Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome

We report 2 cases of apixaban use as prophylaxis against thromboembolism in the nephrotic syndrome (NS), and review the existing literature on direct-acting oral anticoagulant (DOAC) use in this scenario. Our cases appear to be the first reported use of apixaban as prophylaxis against thromboembolis...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Kidney Int Rep
Auteurs principaux: Sexton, Donal J., de Freitas, Declan G., Little, Mark A., McHugh, Tomas, Magee, Colm, Conlon, Peter J., O’Seaghdha, Conall M.
Format: Artigo
Langue:Inglês
Publié: Elsevier 2018
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6035159/
https://ncbi.nlm.nih.gov/pubmed/29989039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2018.02.010
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires